Barry William Hancock
Research Subjects
Barry William Hancock has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
John Tidy
Director, Sheffield Trophoblastic Disease Centre, UK
4 shared publications- Paul Lorigan
The Christie NHS Foundation Trust, Manchester, UK
3 shared publications Carolyn North
YCR Department of Clinical Oncology, Weston Park Hospital, Sheffield, S10 2SJ, United Kingdom
2 shared publicationsJ. M. Horsman
Academic Unit Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK
2 shared publicationsNarendra Pisal
Department of Womens Health, Whittington Hospital, London, N19 5NE, United Kingdom
2 shared publicationsR E Coleman
Academic Unit of Clinical Oncology, Cancer Research Centre, University of Sheffield, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
2 shared publications
Latest Publications
- 1 July 2021
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 74, 131-148
Placental site trophoblastic tumour and epithelioid trophoblastic tumour
- 1 July 2021
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 74, 131-148
Placental site trophoblastic tumour and epithelioid trophoblastic tumour
- 1 February 2017
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 17 (2) , 108-119
Improving Survival of Patients With Hodgkin Lymphoma Over 4 Decades: Experience of the British National Lymphoma Investigation (BNLI) With 6834 Patients
- 1 February 2017
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 17 (2) , 108-119
Improving Survival of Patients With Hodgkin Lymphoma Over 4 Decades: Experience of the British National Lymphoma Investigation (BNLI) With 6834 Patients
- Open Access
- 22 February 2012
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 40 (6) , 2075-2080
Primary thyroid lymphoma: The 40 year experience of a UK lymphoma treatment centre
We report the 40-year unselected experience of a UK lymphoma treatment centre. Between 1970 and 2010, 3363 cases of non-Hodgkin lymphoma were managed by the Sheffield Lymphoma Team. Seventy cases of primary thyroid lymphoma were identified during this time. This retrospective review of the clinical and pathological features of patients with thyroid lymphoma comprises one of the largest series conducted in the UK. The series included 57 females and 13 males with a median age at diagnosis of 69.5. The pathological subtypes were diffuse large B-cell lymphoma (DLBCL) in 50 patients, MALT lymphoma in 13, indolent B-cell lymphoma not otherwise specified (NOS) in 6 and T cell lymphoma in one patient. Of the 64 patients fully staged, 53 had Stage IE and 11 Stage IIE disease. Management modalities included surgery, chemotherapy, radiotherapy or combination treatment. Five- year survival rates for DLBCL, MALT lymphoma and indolent B-cell lymphoma NOS were 45%, 62% and 75%, respectively, with a median overall survival of all histological subtypes of 68 months (range 0-148) or 5.7 years. The outcomes of this series confirm previous experience. If treatment is needed after surgery radiotherapy alone is sufficient for Stage I and II low grade thyroid lymphoma. Combination chemotherapy or adequate chemotherapy followed by radiotherapy is warranted in high grade thyroid lymphoma.
- 22 February 2012
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 40 (6) , 2075-2080
Open AccessPrimary thyroid lymphoma: The 40 year experience of a UK lymphoma treatment centre
We report the 40-year unselected experience of a UK lymphoma treatment centre. Between 1970 and 2010, 3363 cases of non-Hodgkin lymphoma were managed by the Sheffield Lymphoma Team. Seventy cases of primary thyroid lymphoma were identified during this time. This retrospective review of the clinical and pathological features of patients with thyroid lymphoma comprises one of the largest series conducted in the UK. The series included 57 females and 13 males with a median age at diagnosis of 69.5. The pathological subtypes were diffuse large B-cell lymphoma (DLBCL) in 50 patients, MALT lymphoma in 13, indolent B-cell lymphoma not otherwise specified (NOS) in 6 and T cell lymphoma in one patient. Of the 64 patients fully staged, 53 had Stage IE and 11 Stage IIE disease. Management modalities included surgery, chemotherapy, radiotherapy or combination treatment. Five- year survival rates for DLBCL, MALT lymphoma and indolent B-cell lymphoma NOS were 45%, 62% and 75%, respectively, with a median overall survival of all histological subtypes of 68 months (range 0-148) or 5.7 years. The outcomes of this series confirm previous experience. If treatment is needed after surgery radiotherapy alone is sufficient for Stage I and II low grade thyroid lymphoma. Combination chemotherapy or adequate chemotherapy followed by radiotherapy is warranted in high grade thyroid lymphoma.
- 1 January 2010
- Published by Spandidos Publications in Oncology Letters
- Vol. 1 (1) , 187-188
The Mantle Cell Lymphoma International Prognostic Index: Does it work in routine practice?
The Mantle Cell Lymphoma International Prognostic Index (MIPI) combines four factors to differentiate low-, intermediate- and high-risk prognostic groups in advanced mantle cell lymphoma using data from patients treated in clinical trials. To evaluate its use in routine practice, we applied the simplified index retrospectively to 50 consecutive new patients attending our lymphoma service. In the log-rank and multiple comparison statistical tests there was favorable differentiation between survival curves, and particularly between the high- and low-risk groups. We concluded that the MIPI is of value in routine lymphoma practice.
- 1 January 2010
- Published by Spandidos Publications in Oncology Letters
- Vol. 1 (1) , 187-188
The Mantle Cell Lymphoma International Prognostic Index: Does it work in routine practice?
The Mantle Cell Lymphoma International Prognostic Index (MIPI) combines four factors to differentiate low-, intermediate- and high-risk prognostic groups in advanced mantle cell lymphoma using data from patients treated in clinical trials. To evaluate its use in routine practice, we applied the simplified index retrospectively to 50 consecutive new patients attending our lymphoma service. In the log-rank and multiple comparison statistical tests there was favorable differentiation between survival curves, and particularly between the high- and low-risk groups. We concluded that the MIPI is of value in routine lymphoma practice.
- Open Access
- 23 September 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (1) , S96-S97
Survival from kidney cancer in England and Wales up to 2001
- 23 September 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (1) , S96-S97
Open AccessSurvival from kidney cancer in England and Wales up to 2001
- Open Access
- 14 May 2007
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 1 (1) , 21
Atrial and placental melanoma metastasis: a case report and literature review
Malignant melanoma can metastasize to virtually any organ of the body. The aggressiveness is determined by the primary site, depth of dermal invasion, presence or absence of ulceration, lymphovascular infiltration and regional lymph node involvement. We report a case of a pregnant woman with a previous history of stage 3 melanoma who presented with cardiac metastasis and placental melanoma infiltration. A review of literature on cardiac and placental involvement of melanoma is also provided.
- 14 May 2007
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 1 (1) , 21
Open AccessAtrial and placental melanoma metastasis: a case report and literature review
Malignant melanoma can metastasize to virtually any organ of the body. The aggressiveness is determined by the primary site, depth of dermal invasion, presence or absence of ulceration, lymphovascular infiltration and regional lymph node involvement. We report a case of a pregnant woman with a previous history of stage 3 melanoma who presented with cardiac metastasis and placental melanoma infiltration. A review of literature on cardiac and placental involvement of melanoma is also provided.
- 1 November 2006
- Vol. 51 (11) , 859-60
hCG measurement in gestational trophoblastic neoplasia: a critical appraisal.
- 1 November 2006
- Vol. 51 (11) , 859-60
hCG measurement in gestational trophoblastic neoplasia: a critical appraisal.
- 1 October 2006
- Vol. 51 (10) , 825-8
Twin mole and viable fetus: The case for misdiagnosis.
To report the Sheffield Trophoblast Centre experience of twin molar gestations and review this in the light of international experience. Thirty patients with possible twin molar gestations were registered from 1986 to 2004 (during which period 7,200 cases of mole were seen). The accuracy of suspected clinical and histologic diagnoses was investigated. In 10 cases twin mole/fetus had been suspected clinically but not confirmed when products of conception were examined. In 3 of these cases the pregnancy had been therapeutically terminated because of clinical (ultrasound) suspicion of coexisting molar pregnancy. In the 19 cases where twin mole/fetus was suspected, central histopathology review was possible in 14 cases. Only 7 were confirmed. In 2 further cases twin molar gestation was diagnosed on specimens referred for central review as partial mole singleton pregnancies. For confirmed cases the pregnancy outcome was term delivery in 5 cases and miscarriage in 4. Clinical and histopathologic diagnosis of twin molar pregnancies is inaccurate in many suspected cases; therefore, a second (expert) opinion should be sought. When the diagnosis is accurate, maternal and fetal complications are common. However, in suspected cases the pregnancy may be allowed to proceed, with caution, if the mother wishes.
- 1 October 2006
- Vol. 51 (10) , 825-8
Twin mole and viable fetus: The case for misdiagnosis.
To report the Sheffield Trophoblast Centre experience of twin molar gestations and review this in the light of international experience. Thirty patients with possible twin molar gestations were registered from 1986 to 2004 (during which period 7,200 cases of mole were seen). The accuracy of suspected clinical and histologic diagnoses was investigated. In 10 cases twin mole/fetus had been suspected clinically but not confirmed when products of conception were examined. In 3 of these cases the pregnancy had been therapeutically terminated because of clinical (ultrasound) suspicion of coexisting molar pregnancy. In the 19 cases where twin mole/fetus was suspected, central histopathology review was possible in 14 cases. Only 7 were confirmed. In 2 further cases twin molar gestation was diagnosed on specimens referred for central review as partial mole singleton pregnancies. For confirmed cases the pregnancy outcome was term delivery in 5 cases and miscarriage in 4. Clinical and histopathologic diagnosis of twin molar pregnancies is inaccurate in many suspected cases; therefore, a second (expert) opinion should be sought. When the diagnosis is accurate, maternal and fetal complications are common. However, in suspected cases the pregnancy may be allowed to proceed, with caution, if the mother wishes.
- Open Access
- 7 February 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (4) , 469-472
High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening
- 7 February 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (4) , 469-472
Open AccessHigh incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening
- 1 October 2005
- Published by Elsevier in Gynecologic Oncology
- Vol. 99 (1) , 251
Response to the letter to the editor by van Trommel et al.
- 1 October 2005
- Published by Elsevier in Gynecologic Oncology
- Vol. 99 (1) , 251
Response to the letter to the editor by van Trommel et al.